| 2,497 | 71 | 62 |
| 下载次数 | 被引频次 | 阅读次数 |
心血管疾病是全球范围内发病率和致死率最高的疾病，黄芪作为心血管疾病治疗中的常用药物，其药理机制研究备受关注。目前发现黄芪及其化合物具有抗炎、抗氧化应激、抗纤维化、调整糖脂代谢、调节钙钾离子转运、促进血管生成等多重作用，以保护心血管组织细胞免受各种病理因素损伤，阻滞各种病理过程导致的心血管结构异常重塑，促进病理损伤后心血管再生，并维持心血管物质代谢稳态。基于此，本文综述了近10年黄芪发挥上述作用防治心血管疾病的相关作用机制，以期推动黄芪在心血管疾病防治中的机制研究及药物临床转化。
Abstract：The morbidity and mortality of cardiovascular diseases are high worldwide. Huangqi(黄芪) is common medicinal for cardiovascular diseases, and the pharmacological mechanism has attracted the interest of scholars. Huangqi and its effective components have anti-inflammatory, anti-oxidative stress, anti-fibrosis, glucolipid metabolism-regulating, calcium and potassium ion transport-modulating, and angiogenesis-promoting functions. As a result, it can protect the cardiovascular cells from the injury by various pathological factors, block various pathological processes-caused abnormal remodeling of cardiovascular structures, improve cardiovascular regeneration after pathological damage, and maintain the metabolic homeostasis of cardiovascular substances. This paper reviews the pharmacological mechanisms of Huangqi in the prevention and treatment of cardiovascular diseases in recent 10 years, which is expected to promote the research on the mechanisms of this medicinal in the prevention and treatment of cardiovascular diseases and clinical transformation of Huangqi in the treatment of the diseases.
[1]Cui H,Miao S,Esworthy T,et al.3D bioprinting for cardiovascular regeneration and pharmacology[J].Adv Drug Deliv Rev,2018,132:252-269.
[2]Go A S,Mozaffarian D,Roger V L,et al.American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Heart disease and stroke statistics——2014 update:a report from the American Heart Association[J].Circulation,2014,129(3):e28-e292.
[3]高佳明，吕明，解微微，等.中医药心脑血管疾病同治的方剂用药规律分析[J].中国中药杂志，2019,44(1):193-198.
[4]Su H F,Shaker S,Kuang Y,et al.Phytochemistry and cardiovascular protective effects of Huang-Qi (Astragali Radix)[J].Med Res Rev,2021,41(4):1999-2038.
[5]ZHENG Q,ZHU J Z,BAO X Y,et al.A Preclinical Systematic Review and Meta-Analysis of Astragaloside IV for Myocardial Ischemia/Reperfusion Injury[J].Front Physiol,2018,9:795.
[6]YIN B,HOU X W,LU M L.Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways[J].Acta Pharmacol Sin,2019,40(5):599-607.
[7]HUANG H,LAI S,WAN Q,et al.Astragaloside IV protects cardiomyocytes from anoxia/reoxygenation injury by upregulating the expression of Hes1 protein[J].Can J Physiol Pharmacol,2016 ,94(5):542-553.
[8]LI B,YU J,LIU P,et al.Astragaloside IV protects cardiomyocytes against hypoxia injury via HIF-1α and the JAK2/STAT3 pathway[J].Ann Transl Med,2021,9(18):1435.
[9]GONG L,CHANG H,ZHANG J,et al.Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a[J].Cell Physiol Biochem,2018,49(6):2240-2253.
[10]LU M,TANG F,ZHANG J,et al.Astragaloside IV attenuates injury caused by myocardial ischemia/reperfusion in rats via regulation of toll-like receptor 4/nuclear factor-κB signaling pathway[J].Phytother Res,2015,29(4):599-606.
[11]YANG P,ZHOU Y,XIA Q,et al.Astragaloside IV Regulates the PI3K/Akt/HO-1 Signaling Pathway and Inhibits H9c2 Cardiomyocyte Injury Induced by Hypoxia-Reoxygenation[J].Biol Pharm Bull,2019 ,42(5):721-727.
[12]PIAO Y L,LIANG X C.Astragalus membranaceus injection combined with conventional treatment for viral myocarditis:a systematic review of randomized controlled trials[J].Chin J Integr Med,2014,20(10):787-791.
[13]ZHENG Q,ZHUANG Z,WANG Z H,et al.Clinical and Preclinical Systematic Review of Astragalus Membranaceus for Viral Myocarditis[J].Oxid Med Cell Longev,2020,2020:1560353.
[14]刘天龙，刘小玲，张勇，等.黄芪三萜皂苷对CVB3诱导病毒性心肌炎的保护作用研究[J].中国医院药学杂志，2018,38(20):2101-2106.
[15]刘天龙，刘小雷.黄芪三萜皂苷通过抑制TGF-β1/Smad2、p38MAPK信号抑制CVB3病毒诱导的心肌纤维化[J].中国循环杂志，2018,33(S1):19.
[16]刘灏，呼日乐巴特，熊英，等.黄芪总黄酮对病毒性心肌炎小鼠心律失常与内质网应激因子的影响[J].中国应用生理学杂志，2018,34(1):16-18,22.
[17]LIU T,YANG F,LIU J,et al.Astragaloside IV reduces cardiomyocyte apoptosis in a murine model of coxsackievirus B3-induced viral myocarditis[J].Exp Anim,2019,68(4):549-558.
[18]JIA Y,ZUO D,LI Z,et al.Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway[J].Chem Pharm Bull (Tokyo),2014,62(1):45-53.
[19]LUO L F,GUAN P,QIN L Y,et al.Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling[J].Mol Cell Biochem,2021,476(7):2603-2611.
[20]LIN J,FANG L,LI H,et al.Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress[J].Eur J Pharmacol,2019,859:172490.
[21]REN Q,ZHAO S,REN C,et al.Astragalus polysaccharide alleviates LPS-induced inflammation injury by regulating miR-127 in H9c2 cardiomyoblasts[J].Int J Immunopathol Pharmacol,2018,32:2058738418759180.
[22]Zhang W J,Frei B.Astragaloside IV inhibits NF-κB activation and inflammatory gene expression in LPS-treated mice[J].Mediators Inflamm,2015,2015:274314.
[23]ZHAO P,WANG Y,ZENG S,et al.Protective effect of astragaloside IV on lipopolysaccharide-induced cardiac dysfunction via downregulation of inflammatory signaling in mice[J].Immunopharmacol Immunotoxicol,2015,37(5):428-433.
[24]JIANG Y H,SUN W,LI W,et al.Calycosin-7-O-β-D-glucoside promotes oxidative stress-induced cytoskeleton reorganization through integrin-linked kinase signaling pathway in vascular endothelial cells[J].BMC Complement Altern Med,2015,15:315.
[25]XU C,TANG F,LU M,et al.Astragaloside IV improves the isoproterenol-induced vascular dysfunction via attenuating eNOS uncoupling-mediated oxidative stress and inhibiting ROS-NF-κB pathways[J].Int Immunopharmacol,2016,33:119-127.
[26]GUAN F Y,YANG S J,LIU J,et al.Effect of astragaloside IV against rat myocardial cell apoptosis induced by oxidative stress via mitochondrial ATP-sensitive potassium channels[J].Mol Med Rep,2015,12(1):371-376.
[27]HAN R,TANG F,LU M,et al.Astragalus polysaccharide ameliorates H2O2-induced human umbilical vein endothelial cell injury[J].Mol Med Rep,2017,15(6):4027-4034.
[28]QIU L H,ZHANG B Q,LIAN M J,et al.Vascular protective effects of Astragalus membranaceus and its main constituents in rats with chronic hyperhomocysteinemia[J].Exp Ther Med,2017,14(3):2401-2407.
[29]LIN X P,CUI H J,YANG A L,et al.Astragaloside IV Improves Vasodilatation Function by Regulating the PI3K/Akt/eNOS Signaling Pathway in Rat Aorta Endothelial Cells[J].J Vasc Res,2018,55(3):169-176.
[30]SHENG S,XU J,LIANG Q,et al.Astragaloside IV Inhibits Bleomycin-Induced Ferroptosis in Human Umbilical Vein Endothelial Cells by Mediating LPC[J].Oxid Med Cell Longev,2021,2021:6241242.
[31]MA Y,ZHAO Y,ZHANG R,et al.Astragaloside IV inhibits PMA-induced EPCR shedding through MAPKs and PKC pathway[J].Immunopharmacol Immunotoxicol,2017,39(3):148-156.
[32]CHEN Z,CAI Y,ZHANG W,et al.Astragaloside IV inhibits platelet-derived growth factor-BB-stimulated proliferation and migration of vascular smooth muscle cells via the inhibition of p38 MAPK signaling[J].Exp Ther Med,2014,8(4):1253-1258.
[33]ZHANG B,HAO Z,ZHOU W,et al.Formononetin protects against ox-LDL-induced endothelial dysfunction by activating PPAR-γ signaling based on network pharmacology and experimental validation[J].Bioengineered,2021,12(1):4887-4898.
[34]MA C,ZHANG J,YANG S,et al.Astragalus Flavone Ameliorates Atherosclerosis and Hepatic Steatosis Via Inhibiting Lipid-Disorder and Inflammation in apoE-/- Mice[J].Front Pharmacol,2020,11:610550.
[35]QIN H,LIU P,LIN S.Effects of Astragaloside IV on the SDF-1/CXCR4 Expression in Atherosclerosis of apoE(-/-) Mice Induced by Hyperlipaemia[J].Evid Based Complement Alternat Med,2015,2015:385154.
[36]秦合伟，张勤生，李彦杰，等.黄芪甲苷调控miR-17-5p与PCSK9/VLDLR信号通路抗动脉粥样硬化的分子机制研究[J].中国中药杂志，2022,47(2):492-498.
[37]YANG J,WANG H X,ZHANG Y J,et al.Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF-кB signaling pathway in isoproterenol-induced myocardial hypertrophy[J].J Ethnopharmacol,2013,150(3):1062-1070.
[38]HAN R,TANG F,LU M,et al.Protective effects of Astragalus polysaccharides against endothelial dysfunction in hypertrophic rats induced by isoproterenol[J].Int Immunopharmacol,2016,38:306-312.
[39]DAI H,JIA G,LIU X,et al.Astragalus polysaccharide inhibits isoprenaline-induced cardiac hypertrophy via suppressing Ca2+-mediated calcineurin/NFATc3 and CaMKII signaling cascades[J].Environ Toxicol Pharmacol,2014,38(1):263-271.
[40]LUAN A,TANG F,YANG Y,et al.Astragalus polysaccharide attenuates isoproterenol-induced cardiac hypertrophy by regulating TNF-α/PGC-1α signaling mediated energy biosynthesis[J].Environ Toxicol Pharmacol,2015,39(3):1081-1090.
[41]LIU Z H,LIU H B,WANG J.Astragaloside IV protects against the pathological cardiac hypertrophy in mice[J].Biomed Pharmacother,2018,97:1468-1478.
[42]Yunzhi C,Jiaxu C,Jie G,et al.Effect of astragaloside on vitamin D-receptor expression after endothelin-1-induced cardiomyocyte injury[J].Afr J Tradit Complement Altern Med,2017,14(4):278-288.
[43]王焕珍，张惠鹏，赵东亮，等.黄芪甲苷对肥大心肌细胞表面积及维生素D轴相关基因表达的影响[J].时珍国医国药，2018,29(4):799-802.
[44]LU J,WANG Q Y,ZHOU Y,et al.AstragalosideⅣ against cardiac fibrosis by inhibiting TRPM7 channel[J].Phytomedicine,2017,30:10-17.
[45]JIA G,LENG B,WANG H,et al.Inhibition of cardiotrophin1 overexpression is involved in the antifibrotic effect of Astrogaloside IV[J].Mol Med Rep,2017,16(6):8365-8370.
[46]DAI H,JIA G,LU M,et al.Astragaloside IV inhibits isoprenalineinduced cardiac fibrosis by targeting the reactive oxygen species/mitogenactivated protein kinase signaling axis[J].Mol Med Rep,2017,15(4):1765-1770.
[47]朱晓雨，王洪新，李佳莘，等.黄芪多糖对大鼠心肌纤维化的保护作用[J].沈阳药科大学学报，2017,34(8):686-693.
[48]GU J,LIU K,LI H,et al.Astragalus saponin attenuates the expression of fibrosis-related molecules in irradiated cardiac fibroblasts[J].Acta Biochim Biophys Sin (Shanghai),2014,46(6):492-501.
[49]魏斓，王陵军，何嘉琪，等.基于AKT/GSK3-β/SNAIL通路探讨黄芪甲苷对心力衰竭心肌纤维化小鼠的保护作用[J].中药新药与临床药理，2021,32(9):1231-1237.
[50]JIN H,JIAO Y,GUO L,et al.Astragaloside IV blocks monocrotalineinduced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling[J].Int J Mol Med,2021,47(2):595-606.
[51]龚晓男，孙洋，王洪新.黄芪甲苷通过Calpain-1/HIF-1α改善野百合碱诱导的肺动脉高压大鼠氧化应激[J].中药药理与临床，2021,37(2):33-38.
[52]刘欢，邓海艳，田小雪，等.黄芪多糖通过抑制钙蛋白酶1/NF-κB信号通路减轻低氧诱导的肺动脉高压小鼠肺炎症反应和纤维化[J].中国药理学与毒理学杂志，2022,36(2):98-107.
[53]张玉坤，何东平.黄芪多糖对野百合碱诱导大鼠肺动脉高压的减缓作用及其机制研究[J].中国药房，2022,33(1):64-68.
[54]李聪，赵坤，张景良，等.黄芪多糖对野百合碱诱导的肺动脉高压大鼠肺动脉血管的保护作用及其机制[J].吉林大学学报(医学版),2021,47(6):1371-1379.
[55]ZHANG L,YANG Y,WANG Y,et al.Astragalus membranaceus extract promotes neovascularisation by VEGF pathway in rat model of ischemic injury[J].Pharmazie,2011,66(2):144-150.
[56]WANG H,ZHANG Y,XIA T,et al.Synergistic promotion of blood vessel regeneration by astragaloside IV and ferulic acid from electrospun fibrous mats[J].Mol Pharm,2013,10(6):2394-2403.
[57]李梦华.黄芪甲苷在心肌梗死大鼠模型中的心肌保护作用[J].科学技术与工程，2021,21(9):3520-3525.
[58]卢飞艳，丁燕子，陈相健，等.黄芪甲苷促进缺氧损伤后人主动脉内皮细胞血管新生的研究[J].南京医科大学学报(自然科学版),2019,39(8):1124-1129.
[59]李玉梅，鲍慧玮，王楚盈，等.黄芪甲苷与阿魏酸合用调控JAK-STAT通路促进血管内皮细胞增殖作用的研究[J].中国比较医学杂志，2019,29(1):1-8.
[60]ZHANG L,LIU Q,LU L,et al.Astragaloside IV stimulates angiogenesis and increases hypoxia-inducible factor-1α accumulation via phosphatidylinositol 3-kinase/Akt pathway[J].J Pharmacol Exp Ther,2011,338(2):485-491.
[61]WU J,KONG M,LOU Y,et al.Simultaneous Activation of Erk1/2 and Akt Signaling is Critical for Formononetin-Induced Promotion of Endothelial Function[J].Front Pharmacol,2021,11:608518.
[62]Huang Y,Kwan K K L,Leung K W,et al.The Extracts and Major Compounds Derived from Astragali Radix Alter Mitochondrial Bioenergetics in Cultured Cardiomyocytes:Comparison of Various Polar Solvents and Compounds[J].Int J Mol Sci,2018,19(6):1574.
[63]LU Y,LI S,WU H,et al.Beneficial effects of astragaloside IV against angiotensin II-induced mitochondrial dysfunction in rat vascular smooth muscle cells[J].Int J Mol Med,2015,36(5):1223-1232.
[64]ZHAO M M,LIAN W W,LI Z,et al.Astragaloside IV Inhibits Membrane Ca2+ Current but Enhances Sarcoplasmic Reticulum Ca2+ Release[J].Am J Chin Med,2017,45(4):863-877.
[65]ZHAO M,SHAO D,YU L,et al.Electrophysiological effect and the gating mechanism of astragaloside IV on L-type Ca(2+) channels of guinea-pig ventricular myocytes[J].Eur J Pharmacol,2015,760:27-35.
[66]ZHAO M,ZHAO J,HE G,et al.Effects of astragaloside IV on action potentials and ionic currents in guinea-pig ventricular myocytes[J].Biol Pharm Bull,2013,36(4):515-521.
[67]JIN Y,CHEN Q,LI X,et al.Astragali Radix protects myocardium from ischemia injury by modulating energy metabolism[J].Int J Cardiol,2014,176(3):1312-1315.
[68]Fernandez M L,Thomas M S,Lemos B S,et al.TA-65,A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic Syndrome[J].Curr Pharm Des,2018,24(17):1905-1911.
[69]CHEN W,LAI Y,WANG L,et al.Astragalus polysaccharides repress myocardial lipotoxicity in a PPARalpha-dependent manner in vitro and in vivo in mice[J].J Diabetes Complications,2015,29(2):164-175.
[70]SUN S,YANG S,AN N,et al.Astragalus polysaccharides inhibits cardiomyocyte apoptosis during diabetic cardiomyopathy via the endoplasmic reticulum stress pathway[J].J Ethnopharmacol,2019,238:111857.
[71]LENG B,TANG F,LU M,et al.Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway[J].Life Sci,2018,209:111-121.
[72]M'kacher R,Breton L,Colicchio B,et al.Benefit of an association of an antioxidative substrate and a traditional chinese medicine on telomere elongation[J].Cell Mol Biol (Noisy-le-grand),2019,65(8):54-58.
[73]西旺，宋楠楠，梁华，章文春.蛋白质组学在中医“气”实质研究中的应用[J].中华中医药杂志，2021,36(2):683-686.
[74]张梅，龚方琴.气概念的本质刍议[J].时珍国医国药，2021,32(2):411-413.
[75]蒋晓林，王必勤，刘昭明，范刚启.从现代分子生物学探讨中医气学理论的实质[J].中医杂志，2003,(8):568-570.
[76]徐先祥，戴岳，刘青云.“气”与细胞通讯[J].世界科学技术-中医药现代化，2007,(6):31-35,21.
[77]张永忠.论中医学人体之气的实质是新陈代谢[J].中国中医基础医学杂志，2000,(5):8-11.
[78]吴昊天，魏聪，常成成，位庚，常丽萍.评述近20年传统医学“气本质”的理论研究进展[J].中国中医基础医学杂志，2016,22(2):281-283,286.
[79]苏文，赵益，朱卫丰，刘红宁.中药及复方对心血管病血液流变学的影响[J].中国实验方剂学杂志，2010,16(15):225-229.
[80]王巧云.黄芪注射液对血瘀证兔血液流变学的影响[J].中药药理与临床，2004,(2):19-20.
[81]薛建欣，严永清，蒋莹.黄芪、归尾、香附、川芎、赤芍等配伍对“血瘀”大鼠血液流变学的影响[J].中国药科大学学报，1994,(2):119.
[82]马旭，张可，韩淑燕，马治中，屠鹏飞.黄芪提取物与红花总黄酮配伍对急性血瘀大鼠血液流变学的改善作用[J].中国药理学与毒理学杂志，2012,26(4):504-509.
[83]邬丹，江从勋，廖诗平，植茂辉，杨芳炬.注射用黄芪冻干粉对心肌缺血大鼠血流动力学及血液流变学的影响[J].华西药学志，2011,26(6):557-560.
[84]LI M,HAN B,ZHAO H,et al.Biological active ingredients of Astragali Radix and its mechanisms in treating cardiovascular and cerebrovascular diseases[J].Phytomedicine,2022,98:153918.
基本信息:
DOI：10.13412/j.cnki.zyyl.20221114.002
中图分类号:R285
引用信息:
[1]张尚祖,刘永琦,李洋洋,等.黄芪防治心血管疾病的作用机制研究进展[J].中药药理与临床,2023,39(10):115-124.DOI:10.13412/j.cnki.zyyl.20221114.002.
基金信息:
国家自然科学基金资助项目(编号：82004094); 中国博士后科学基金项目(编号：2021M693794); 甘肃省“双一流”科研重点项目(编号：GSSYLXM-05); 甘肃省自然科学基金项目(编号：20JR10RA318); 2022年度甘肃省优秀研究生“创新之星”项目(2022CXZX-758)
2022-11-16
2022-11-16
2022-11-16